Mandate

Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North

November 11, 2016

Vinge has advised Smart Eye AB in connection with the listing of Smart Eye’s shares on Nasdaq First North.

In connection with the listing, a new issue of not more than 1 750 000 shares was performed whereupon Smart Eye will receive not more than SEK 80 500 000. The offer is directed to the general public and institutional investors. The prospectus was published on 10 November and the first day of trading is 7 December.

Vinge’s team primarily consisted of responsible partner Anders Strid, Magnus Pauli (client relationship), Frida Bäckegren (project manager due diligence and prospectus), Joel Zetterström and Natalie Bäck (IP), Jonas Lindeblad (employment), Björn Nicolai and Karin Wisenius (EU and competition), Victor Ericsson (tax) and company assistant Camilla Andersson.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024